| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Complanatoside B targets inflammatory pathways, modulating oxidative stress and inhibiting inflammatory mediators. As a flavonoid glycoside, it exhibits anti-inflammatory properties by reducing the production of pro-inflammatory cytokines and mediators. The compound's mechanism involves the modulation of oxidative stress pathways, contributing to its anti-inflammatory effects. Its flavonoid structure allows for interactions with various enzymes and signaling pathways involved in inflammation. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Complanatoside B exhibits anti-inflammatory properties. The compound modulates oxidative stress and inhibits inflammatory mediators in cell-based assays. As a flavonoid glycoside from Astragalus complanatus, its anti-inflammatory effects have been characterized. These in vitro findings support its potential applications in inflammation research and natural product pharmacology. Further studies are needed to fully characterize its mechanisms of action and spectrum of activity.
|
| ln Vivo |
In vivo studies of Complanatoside B are limited as the compound is primarily used as a research chemical. As a flavonoid glycoside from Astragalus complanatus, it may contribute to the pharmacological effects of the plant. Its anti-inflammatory properties suggest potential for in vivo evaluation in models of inflammatory diseases. However, comprehensive in vivo pharmacological studies specifically targeting Complanatoside B are not well documented. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for Complanatoside B typically involve testing its anti-inflammatory activity through measurement of inflammatory mediator production. The compound's ability to modulate oxidative stress is assessed using cell-free systems. Its purity (≥98%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Complanatoside B involve culturing immune cells to evaluate its anti-inflammatory effects. Cells are treated with varying concentrations of the compound and stimulated with inflammatory stimuli. Pro-inflammatory cytokine production is measured by ELISA. Oxidative stress markers are measured using fluorescent probes. Cell viability is assessed using MTT or similar colorimetric assays to ensure that observed effects are not due to cytotoxicity. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Complanatoside B would be conducted to evaluate its anti-inflammatory activity. Animals with induced inflammation would be treated with the compound and inflammatory markers measured. Parameters assessed would include cytokine levels, oxidative stress markers, and tissue histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Complanatoside B reflect its nature as a flavonoid glycoside. It has a molecular weight of 756.66 and the molecular formula C33H40O20. The compound has a purity of ≥98% by HPLC and is stored at 2-8°C. As a glycoside, it may be metabolized by intestinal bacteria to the aglycone. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Complanatoside B has been evaluated in the context of its use as a research chemical. As a naturally occurring flavonoid glycoside from Astragalus complanatus, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of ≥98%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Complanatoside B (CAS# 142473-99-2) has the molecular formula C33H40O20 and a molecular weight of 756.66. The compound is a flavonol glycoside isolated from the seeds of Astragalus complanatus and Phyllolobium chinense Fisch. Complanatoside B is a flavonoid with anti-inflammatory properties. It modulates oxidative stress and inhibits inflammatory mediators. The compound has a purity of ≥98% by HPLC and is stored at 2-8°C. It is intended for research use only.
|
| Molecular Formula |
C33H40O20
|
|---|---|
| Molecular Weight |
756.658712387085
|
| Exact Mass |
756.211
|
| CAS # |
142473-99-2
|
| PubChem CID |
10440090
|
| Appearance |
Off-white to light yellow solid
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
53
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
COC1=CC(=C2C(=C1)OC(=C(C2=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O[C@H]4[C@@H]([C@](CO4)(CO)O)O)C5=CC=C(C=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O
|
| InChi Key |
YCXFPUHHUJNTNY-CUCHOISXSA-N
|
| InChi Code |
InChI=1S/C33H40O20/c1-46-14-6-15(37)19-16(7-14)49-26(12-2-4-13(5-3-12)48-30-25(43)23(41)20(38)17(8-34)50-30)27(22(19)40)52-31-28(24(42)21(39)18(9-35)51-31)53-32-29(44)33(45,10-36)11-47-32/h2-7,17-18,20-21,23-25,28-32,34-39,41-45H,8-11H2,1H3/t17-,18-,20-,21-,23+,24+,25-,28-,29+,30-,31+,32+,33-/m1/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-3-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-7-methoxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
|
| Synonyms |
Complanatoside B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3216 mL | 6.6080 mL | 13.2160 mL | |
| 5 mM | 0.2643 mL | 1.3216 mL | 2.6432 mL | |
| 10 mM | 0.1322 mL | 0.6608 mL | 1.3216 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
